MilliporeSigma Advances Cell Analysis with New Benchtop Flow Cytometer with Camera Detection
- Highly sensitive optical system based on patented technology unique to MilliporeSigma’s Amnis® flow cytometers
- Configurable, 7-laser capacity to meet researchers’ evolving needs
- Laser upgrades quickly performed in lab with no downtime
MilliporeSigma today launched its new CellStream™ benchtop flow cytometry system, a compact, customizable flow cytometer that uses a camera for detection. Its unique optics system and design provide researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles.
“Researchers increasingly require more power and agility in their labs and research capabilities,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma. “MilliporeSigma’s new CellStream™ flow cytometry system expands the limits of sensitivity, allowing scientists to tailor their instrument to their needs in immunology, cancer research and many other areas.”
The CellStreamTM system’s Amnis® time-delay integration and camera technology rapidly captures low-resolution cell images and converts them to high-throughput intensity data with enhanced fluorescence sensitivity. The new system can be used in a wide variety of research areas, including exosome research, where it can identify small populations unable to be seen on other cytometers.
MilliporeSigma developed this new technology with the same patent-protected optics system as its Amnis® flow cytometers, which are used in academic, biotech and pharmaceutical cell analysis and research applications.
The CellStream™ flow cytometry system offers multiple innovative features, including:
- Fully customizable 7-laser capacity provides unparalleled versatility and the capability to obtain up to 22 detection channels.
- Patent-protected TDI sensor and camera technology enables high fluorescence sensitivity.
- The system may be fully and quickly upgraded on-site to add more lasers if needed.
- Standard 96-well plate auto-sampler is available on all instruments to capture high-throughput intensity data.
- Event gallery allows visual verification of cell populations and helps troubleshoot.
The new CellStream™ system expands MilliporeSigma’s portfolio of innovative flow cytometry platforms.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15.3 billion in 2017. Almost 53,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Combined efforts aim to develop an artificial intelligence (AI) technology that detects both schistosomiasis and soil-transmitted helminthiasis